

The problem of publication bias and waste in research

Elizabeth Wager PhD

Publications Consultant, Sideview

EQUATOR Network Fellow

Visiting Professor, University of Split

liz@sideview.demon.co.uk

Themes

- Why does research waste matter?
- When / how does waste occur?
- What harm does research waste do?
- How can we reduce waste in research?




For more details see Lancet series:
<http://www.thelancet.com/series/research>

Research funding is finite



If someone takes a slice there is less left
for everybody else ...

Waste occurs in all stages of research



ed/tage Insights
Resources for researchers and patients


Ethical impacts

1. Asking the wrong questions
2. Weak study designs
3. Not publishing all research
4. Poor reporting quality

ed/tage Insights
Resources for researchers and patients



Sleeping position and sudden infant death




ed/tage Insights



Sleeping position and sudden infant death

Cumulative effect (by year)

Clear effect by 1970 →



Gilbert et al *Int J Epidemiol*
2005;34:874

ed/tage Insights



This mother was right!


- Up to 1988 UK & US books recommended babies should sleep on their front
- But since 1970 there was clear evidence that front sleeping significantly **increased** sudden infant death
- Earlier recognition of risk of front sleeping could have prevented >60,000 infant deaths

ed/tage Insights
Resources for research and journals

Effect of tranexamic acid on blood loss during surgery

Cumulative meta-analysis shows effect by 2001 but trials continue until 2011

Based on Ker et al *BMJ* 2012;**344**:e3054




ed/tage Insights
Resources for research and journals

Asking the wrong question

- Patients undergoing surgery involved in unnecessary trials, some receiving sub-optimal treatment, despite clear evidence that tranexamic acid reduces blood loss
- BUT, despite all the studies, they were too small to show whether tranexamic acid also reduced heart attacks and death

Underpowered studies




Underpowered studies

- Big problem in preclinical (animal) research
- Risk of not detecting true effect and reporting 'false positive' effect
- Systematic reviews found:
3% studies in stroke
0% in Alzheimer's / Parkinson's disease
reported sample size calculation

Underpowered studies

- Meta-analysis of 44 animal studies of fluid resuscitation
- Average number of animals / treatment group was 13
- No trial was large enough to reliably detect a 10% absolute difference (halving) in risk of death




Trial size and smallest absolute risk reduction detectable

Roberts et al *BMJ* 2002;**324**:474



Wasting lab animals

Number of animals	Power	% animals wasted
4	18.6%	81.4%
8	32.3%	67.7%
16	56.4%	43.6%
32	85.1%	14.9%



Chances of wasting an animal in 2-group study seeking 30% reduction in infarct volume with SD = 40%

ed/tage Insights

From CAMARADES

Poor design in animal studies on multiple sclerosis

- Meta-analysis of 1117 publications
 - 9% reported random allocation to group
 - 16% had blinded assessment of outcome
 - <1% had sample size calculation




Vesterinen et al MS 2010;16:1044


ed/tage Insights

Weak design in animal studies over-estimates effect size

Randomization



Blinded assessment



Group size

Review of 1117 studies in multiple sclerosis

Vesterinen et al *MS* 2010;16:1044

ed/tage Insights

Half of all clinical trials are never published

N=677 Trials



Ross et al *PLOS Med* 2009;e1000144

Publication rate may be higher for more recent studies but publication bias affects the literature on most prescribed medicines

ed/tage Insights

Evidence of non-publication of large trials

- 585 registered trials with >500 participants
- Completed before Jan 2009
- 29% (171) unpublished in November 2012
- Of the unpublished trials 78% did not have results posted on CT.gov
- *“The lack of availability of results from these trials ... constitutes **a failure to honour the ethical contract** that is the basis for exposing study participants to the risks inherent in trial participation. Additional safeguards are needed to ensure timely public dissemination of trial data.”*

Jones et al *BMJ* 2013;**347**:f6104

The scale of publication bias

- About 50% of studies presented at conferences never get published in full
(Scherer et al *JAMA* 1994;**272**:158-62)
- Cohort of RCTs submitted to Swiss REC (to 1998) 52% published by 2006
(von Elm et al *Swiss Med Wkly* 2008;**138**:197-203)
- 22% of trials on CT.gov reported results within 1 year of study end
(Prayle et al *BMJ* 2012)

50% of clinical trials unpublished

Of EU-funded health research 1998-2006

- 50% unpublished
- 570 million Euros of research had “no detectable academic output”

Galsworthy et al *Lancet* 2012;**380**:971

- Situation may be improving but evidence-base for most prescribed medicines is badly affected by non-publication

Effects of publication bias

- German drug assessment body found 74% of data on the antidepressant reboxetine was unpublished
- Including the unpublished data changed their recommendation (to “ineffective and potentially harmful”)

Wieseler et al *BMJ* 2010;**341**:c4942
Eyding et al *BMJ* 2010;**341**:c4737

Why does publication bias matter?

- Clinical decisions are based on medical evidence
- If the evidence-base is distorted, the decisions may not be correct
- Guidelines are often based on systematic reviews / meta-analyses – these can be distorted by publication bias


- Publication bias is a major problem
- It is caused by:
 - Non-publication of trials with negative findings
 - Selective publication of positive outcomes
 - (Redundant publication of positive trials)
- It can be reduced by:
 - Trial registration
 - Publishing protocols
 - Rewarding researchers / companies for responsible publication (?punishing non-publication)

Much published research is unusable

- Of 102 journal articles reporting clinical trials, 62% had a change to the primary outcome stated in the protocol
- Of 88 studies using novel questionnaires only 8% of questionnaire could be accessed
- Of 141 studies of test accuracy, 40% did not report participants' age and sex
- Of 49 AIDS trials, only 33% reported all adverse events

All refs in Glasziou et al *Lancet*, 2014

Inadequate treatment descriptions in 80 studies of medical therapies from journal article and **supplementary info**



Conclusions

- Waste in research is a major problem
- Waste is an ethical issue because:
 - research resources are finite
 - patients / volunteers / animals take part in unnecessary studies
 - decisions (affecting patient treatments, public policies) are based on flawed evidence-base (incomplete, biased, misleading reporting)
- Publication bias (selective reporting / non-publication) is a major cause of research waste

How can we reduce waste in research?

- Demand justification of study question
- Support research synthesis so it's clear what is already known
- Enforce trial / study registration
- Use strong designs that maximize the effect-to-bias ratio
- Reward reproducible research
- Reward full and effective dissemination of findings (and re-use of datasets)
- Support use of reporting guidelines



Initiatives to reduce waste in medical research

- Prioritisation / question setting 
- Trial registration [ClinicalTrials.gov](https://clinicaltrials.gov) 
- Full reporting 
- High quality reporting 

ed/tage Insights
Research for evidence and quality



Questions



ed/tage Insights
Research for evidence and quality

Cactus Communications Korea Ltd.

3F, Dowon Bldg, 34, Mapo-daero, Mapo-gu, Seoul, Korea 121-728

T: 02-538-3177 | F: 02-703-3177

www.editage.co.kr

United States | Japan | India | Singapore | South Korea | China